Novartis AG
Research Novartis AG (NOVN) on Bullrun: valuation model: 3.8% undervalued, market cap CHF 221.40B, P/E 22.2, dividend yield 3.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNOVN
- ExchangeSW
- CountrySwitzerland
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyCHF
- Valuation signal3.8% undervalued
- Market capCHF 221.40B
- P/E22.2
- Dividend yield3.1%
- Financial periodQ2 2026
- RevenueUSD 14.95B
- Net incomeUSD 3.26B
- Free cash flowUSD 5.12B
- Gross margin75.2%
Valuation Snapshot
Bullrun's latest valuation model marks Novartis AG as 3.8% undervalued; latest market cap is CHF 221.40B; P/E is 22.2; dividend yield is 3.1%.
Peer valuation comparison
Latest P/E is 22.19x versus a Healthcare sector median of 24.61x (9.8% below).
Latest dividend yield is 3.1% versus a Healthcare sector median of 1.84% (68.5% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 56.67B | USD 13.98B | USD 15.24B | 76.0% | 7.15 | USD 11.44B | USD 35.38B | USD 46.13B |
| FY2024 | USD 51.72B | USD 11.94B | n/a | 75.2% | 5.87 | USD 11.46B | n/a | n/a |
| FY2023 | USD 46.66B | USD 14.85B | n/a | 73.3% | 7.1 | USD 13.39B | n/a | n/a |
| FY2022 | USD 43.46B | USD 6.96B | n/a | 73.4% | 3.17 | USD 7.52B | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-05 | CHF 221.40B | 22.2 | 3.2% | 3.7 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 3.7 CHF, yield 3.1%.
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6);
ETFs that hold Novartis AG
Novartis AG is one of the ten largest holdings of 238 ETFs that investors in Europe can buy. The 8 most traded of them:
| ETF | Weight | TER |
|---|---|---|
| Amundi Core Stoxx Europe 600 UCITS ETF Acc | 1.97% | 0.07% |
| iShares Core MSCI Europe UCITS ETF EUR (Acc) | 2.03% | 0.12% |
| iShares STOXX Europe 600 UCITS ETF (DE) EUR (Dist) | 1.85% | 0.20% |
| iShares Core MSCI Europe UCITS ETF EUR (Dist) | 2.03% | 0.12% |
| iShares Core SPI ETF (CH) | 12.34% | 0.10% |
| Xtrackers MSCI World ex USA UCITS ETF 1C USD | 1.17% | 0.15% |
| iShares Swiss Dividend ETF (CH) | 15.82% | 0.15% |
| Amundi Core MSCI Europe UCITS ETF DR | 2.01% | 0.12% |
Compare every fund on the same index:
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Novartis AG overvalued or undervalued?
Bullrun's valuation model currently marks Novartis AG as 3.8% undervalued.
What is Novartis AG's market cap?
Novartis AG's market capitalization is CHF 221.40B.
What is Novartis AG's P/E ratio?
Novartis AG's price-to-earnings (P/E) ratio is 22.2.
Does Novartis AG pay a dividend?
Novartis AG has a dividend yield of 3.1%.
What does Novartis AG do?
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.